Early combined immunosuppression in Crohn's disease.

摘要

A crucial issue for future studies should be the assessment of infliximab "as a disease-modifying agent rather than in managing active disease.Furthermore, we believe that recently reported concerns about increased risk of hepatosplenic T-cell lymphoma in patients treated simultaneously with infliximab and immunosuppressive therapy5 should have been discussed